In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

Plasma cell populations can be identified based on the expression of CD45, CD38, and the more plasma cell-specific marker CD138. These markers allow plasma cells to be classified as either normal ...

Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).

This composite flow cytometric panel illustrates the bone marrow of a newly diagnosed primary plasma cell leukemia patient demonstrating CD38 +, λ-a-restricted, CD20-plasma cells.

This includes programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is a target for antibody-based therapeutics ... defined as observed Sarclisa plasma concentrations. Notably, ...

Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Brist ...

Methods: An observational study was carried out of laboratory results of adult patients with plasma cell diseases, who underwent aspiration, imprint cytology, flow cytometry (CD38, C138) and biopsy in ...

The first dose of KJ-C2320, an allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD38, has been administered to a patient ... for the treatment of R/R multiple myeloma and plasma ...

Background: Inflammatory myofibroblastic tumors (IMTs) are rare soft-tissue neoplasms. Accordingly, there is no standardized therapy for unresectable or advanced IMT. Chemotherapy, radiotherapy, and ...